1. Home
  2. BHVN

BHVN

Biohaven Ltd.

Logo Biohaven Ltd.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 1:48pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Founded: 2013 Country:
United States
United States
Employees: N/A City: NEW HAVEN
Market Cap: 3.7B IPO Year: 2017
Target Price: $51.50 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -5.73 EPS Growth: N/A
52 Week Low/High: $12.35 - $62.21 Next Earning Date: 05-10-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -72.48%

Share on Social Networks: